scholarly journals Research Progress of Renal Cancer

2021 ◽  
Vol 5 (6) ◽  
pp. 34-37
Author(s):  
Ya Liu ◽  
Ping Fan
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cancer ◽  
Renal Cell ◽  
Medical Technology ◽  
Diagnosis And Treatment ◽  
Research Progress ◽  
Urinary System

Renal cell carcinoma (RCC) is one of the most common tumors of the urinary system. With the development of medical technology, the diagnostic rate and incidence of RCC are increasing year by year. This article reviews the latest research progress in the diagnosis and treatment of renal cell carcinoma.

scholarly journals Embelin Enhances the Sensitivity of Renal Cancer Cells To Axitinib by Inhibiting HIF-1α Signaling Pathway

2021 ◽  
Author(s):  
Qiong Fang ◽  
Zhiying Li ◽  
Ye Xue ◽  
Xin Zong ◽  
Wenshuang Ma ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Cancer Cells ◽  
Renal Cancer ◽  
Renal Cell ◽  
High Recurrence Rate ◽  
Urinary System ◽  
Regulatory Pathways ◽  
Targeted Drug ◽  
Clinical Drugs

Abstract Background Renal cell carcinoma (RCC) is a common malignant tumor of urinary system with high recurrence rate and easy metastasis. Current clinical drugs for renal cell carcinoma include immunotherapy and targeted drugs. Axitinib is a clinical targeted drug for the treatment of renal cell carcinoma, which has some shortcomings such as unstable efficacy and easy drug resistance. The aim of this study was to determine whether embelin can enhance the sensitivity of renal cancer cells to axitinib and explore its regulatory pathways. Results Embelin enhanced the sensitivity of renal cancer cells to axitinib in the following aspects: enhancing the inhibition of cell proliferation by axitinib, the ability to kill cancer cells, and the induction of cell apoptosis. HIF-1α was a potential pathway of Embelin action. After IOX2 regulated the HIF-1α pathway, the enhancing effect of embelin on axitinib was weakened. Conclusions Embelin enhanced the sensitivity of both A498 and 786-O renal cancer cells to axitinib by inhibiting the HIF-1α pathway.

Effect of host immunity on metastatic potential in renal cell carcinoma: the assessment of optimal in vivo models to study metastatic behavior of renal cancer cells

Tumor Biology ◽  
2012 ◽  
Vol 33 (2) ◽  
pp. 551-559 ◽  
Author(s):  
Minoru Kobayashi ◽  
Tatsuo Morita ◽  
Nicole A. L. Chun ◽  
Aya Matsui ◽  
Masafumi Takahashi ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Cancer Cells ◽  
Renal Cancer ◽  
Renal Cell ◽  
Metastatic Potential ◽  
Host Immunity ◽  
In Vivo Models ◽  
Metastatic Behavior

scholarly journals The Diagnosis and Treatment of Renal Cell Carcinoma

Cancer ◽  
1980 ◽  
Vol 45 ◽  
pp. 1947-1956 ◽  
Author(s):  
JEAN B. DeKERNION ◽  
DAVID BERRY
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Diagnosis And Treatment

scholarly journals Thyroid Metastases from Renal Cell Carcinoma: Review of the Literature

2010 ◽  
Vol 10 ◽  
pp. 590-602 ◽  
Author(s):  
Alessandro Sindoni ◽  
Massimo Rizzo ◽  
Giovanni Tuccari ◽  
Antonio Ieni ◽  
Valeria Barresi ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cancer ◽  
Renal Cell ◽  
Left Kidney ◽  
Thyroid Lobe ◽  
Thyroid Metastasis ◽  
Side Preference ◽  
Thyroid Metastases ◽  
The Right

The thyroid gland is a rare site of clinically detectable tumor metastasis and kidneys are frequently the site of the parent malignancy. In the present review on thyroid metastases from renal cell carcinoma, cases were searched on PubMed by entering the strings: “renal carcinoma [or“hypernephroma”] AND thyroid metastasis/metastases”. Thus, we retrieved a total of 111 cases that were published between 1964 and 2007, a total that became 113 by adding two patients observed by us. The female to male ratio was 1.35:1. The primary renal cancer was almost always unilateral (90%) (with no significant side preference) and only rarely bilateral (9% in men, 4% in women), whereas bilaterality of thyroid metastases was relatively more frequent (28%). Thyroid metastasis from renal cancer was commonly single with a unique node that appears solid and hypoechoic at ultrasonography, approximately 9 years after nephrectomy. Concordance of lateralization was insignificantly greater for the right kidney/right thyroid lobe pattern (54%) than for the left kidney/left thyroid lobe pattern (40%), regardless of gender. Finally, survival was longer for women. Thyroid metastases, even if rare in the clinical practice, must be considered in the differential diagnosis of a thyroid nodule, particularly in patients who have a history of malignancies.

scholarly journals Circular RNA circMTO1 Suppresses RCC Cancer Cell Progression via miR9/LMX1A Axis

2020 ◽  
Vol 19 ◽  
pp. 153303382091428
Author(s):  
Kecheng Li ◽  
Cheng-Liang Wan ◽  
Yan Guo
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Proliferation ◽  
Cell Carcinoma ◽  
Cancer Cells ◽  
Renal Cancer ◽  
Renal Cell ◽  
Target Genes ◽  
Cell Function ◽  
Circular Rnas ◽  
Promoting Effect

Renal cell carcinoma is one of the most common kidney cancer, which accounts almost 90% of the adult renal malignancies worldwide. In recent years, a new class of endogenous noncoding RNAs, circular RNAs, exert important roles in cell function and certain types of pathological responses, especially in cancers, generally by acting as a microRNA sponge. Circular RNAs could act as sponge to regulate the microRNA and the target genes. However, the knowledge about circular RNAs in renal cell carcinoma remains unclear so far. In the research, we selected a highly expressed novel circular RNAs named circMTO1 in renal cell carcinomas. We investigated the roles of circMTO1 and found that circMTO1 overexpression could suppress cell proliferation and metastases in both A497 and 786-O renal cancer cells, while silencing of circMTO1 could promote the progression in SN12C and OS-RC-2 renal cancer cells. The study showed that circMTO1 acted as miR9 and miR223 sponge and inhibited their levels. Furthermore, silencing of circMTO1 in renal cell carcinoma could downregulate LMX1A, the target of miR-9, resulting in the promotion of renal cell carcinoma cell proliferation and invasion. In addition, LMX1A expression suppression induced by transfection of miR9 mimics confirmed that miR9 exerted its function in renal cell carcinoma by regulating LMX1A expression. What’s more, miR9 inhibitor and LMX1A overexpression could block the tumor-promoting effect of circMTO1 silencing. In conclusion, circMTO1 suppresses renal cell carcinoma progression by circMTO1/miR9/ LMX1A, indicating that circMTO1 may be a potential target in renal cell carcinoma therapy.

Late Recurrence of Renal Cell Carcinoma: Retrospective and Collaborative Study of the Japanese Society of Renal Cancer

Urology ◽  
2011 ◽  
Vol 77 (2) ◽  
pp. 379-384 ◽  
Author(s):  
Noriomi Miyao ◽  
Seiji Naito ◽  
Seiichiro Ozono ◽  
Nobuo Shinohara ◽  
Naoya Masumori ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cancer ◽  
Renal Cell ◽  
Japanese Society ◽  
Collaborative Study ◽  
Late Recurrence

Mechanism of Telomerase Reverse Transcriptase Regulating Dendritic Cell Immune Function in Proliferation and Cell Cycle of Renal Cell Carcinoma

2020 ◽  
Vol 10 (2) ◽  
pp. 195-202
Author(s):  
Yunxing Liu
Keyword(s):  
Cell Cycle ◽  
Renal Cell Carcinoma ◽  
Flow Cytometry ◽  
Cell Carcinoma ◽  
Cancer Cell ◽  
Renal Cancer ◽  
Renal Cell ◽  
Human Renal Cell Carcinoma ◽  
Renal Cancer Cell ◽  
Group A

To select human renal cell carcinoma cell lines VMRC-RCZ After resuscitation, culture and passage, the cell concentration was adjusted to 1 × 106/ml, and the experiment was divided into a control group, a renal cancer cell + DC group (DC group), and a renal cancer cell + DC+ hTERTtransfection group (transfection Group), a total of 3 groups; the recombinant eukaryotic expression plasmid hTERT-IRES2-EGFP was constructed and transfected into mature DC; the renal cancer cell + DC group was transfected with the empty plasmid, and the renal cancer cell + DC+ hTERT transfection group was transfected with the overexpression plasmid The transfection efficiency was detected by RT-PCR method. Cultured for 12 h and 24 h respectively, the percentage of HLA-DR, CD40 and MHC-II molecules in three groups of DC immunophenotypes was determined according to flow cytometry assay, and the cytokines IL-12 and TNF-α expression level, DC apoptosis rate was detected by in situ hybridization, the rate of tumor cell proliferation was measured according to MTT method, and cell cycle was determined through flow cytometry.

Sign in / Sign up

Export Citation Format

Share Document